Summary
How do digital twins in medicine get from the lab to the patient? It all comes down to regulation, data, and trust. In this second part with Dr. Andrée Bates (CEO, Eularis), we cover the FDA Modernization Act 2022, EU AI Act conflicts with GDPR, the UK and China regulatory landscape, digital twin ownership and liability, patient-owned health data, decentralized data markets, and what it will take — technically and culturally — to make AI-powered personalized medicine real. Plus: why medical school curricula must change, and a vision of the human-AI health future. Don't miss Part 1 (EP 79) for the science and economics foundation.
Key Takeaways
- The FDA's 2022 Modernization Act was a watershed moment — it replaced mandatory animal testing with "non-clinical" methods including in silico and cell-based models.
- 90% of drugs that clear animal studies never make it through human trials
- The EU faces a three-way regulatory conflict — the AI Act, the Medical Device Regulation (MDR), and GDPR have overlapping, partially conflicting requirements; GDPR's "purpose limitation" principle is structurally hostile to digital twins, which are by definition continuously updated
- US vs. EU regulatory philosophy in one sentence: the US is outcome-based and post-market weighted ("prove it works, monitor it"); the EU is process-based and pre-market weighted ("prove your development was rigorous first") — with real consequences for patient access timelines
- China is the one to watch — the NMPA accepts in silico evidence, data sharing is state-encouraged, and population-scale twins built on integrated health records are politically feasible in a way they are not in the West
- Ownership of digital twins is unresolved
- Patients owning their own health data — including blockchain-based consent models where patients sell data case-by-case to pharma — is already being piloted in the US
- The full ecosystem for digital twins requires: multi-organ integration, quantum computing power, privacy-preserving AI (e.g. federated learning), faster regulatory qualification pathways, international harmonization, and a liability framework
- The cultural gap is the hardest barrier — public trust in computer-tested drugs lags far behind trust in animal- or human-tested ones; the first major in silico drug recall, when it happens, will be a defining political moment
- Medical education must change — tomorrow's clinicians need to read computational evidence confidently; few medical schools teach this yet
Guest Bio — Dr. Andrée Bates
Dr. Andrée Bates is the Chairwoman, Founder, and CEO of Eularis, AI consultancy for the pharmaceutical and life sciences industry. She hosts her own podcast with over 220 episodes on AI in pharma.
00:00 Introduction to PART 2 with Andree Bates
01:35 Regulatory Landscape for AI and Digital Twins
05:22 Comparative Analysis of US and EU Regulations
10:48 Global Perspectives on AI in Healthcare
14:08 Future of Personal Data Ownership in Medicine
17:43 Innovative Business Models for Digital Twins
21:17 The Role of AI and Quantum Computing in Healthcare
27:31 Building the Future of Medicine: Preconditions and Infrastructure
Hyperlinks:
AI in Pharma — search on Spotify/Apple Podcasts (220+ episodes)
Anastassia Lauterbach - LinkedIn
First Public Reading, Romy, Roby and the Secrets of Sleep (1/3)
First Public Reading, Romy, Roby and the Secrets of Sleep (2/3)
First Public Reading, Romy, Roby and the Secrets of Sleep (3/3)
